These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35115509)

  • 1. The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression.
    Guo Y; Zhu H; Xiao Y; Guo H; Lin M; Yuan Z; Yang X; Huang Y; Zhang Q; Bai Y
    Cell Death Dis; 2022 Feb; 13(2):112. PubMed ID: 35115509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy of niclosamide with gemcitabine inhibited cell proliferation and apoptosis via Wnt/β-catenin/c-Myc signaling pathway by inducing β-catenin ubiquitination in pancreatic cancer.
    Kang HW; Kim JH; Lee DE; Lee YS; Kim MJ; Kim HS; Fang S; Lee BE; Lee KJ; Yoo J; Kim HJ; Park JS
    Cancer Biol Ther; 2023 Dec; 24(1):2272334. PubMed ID: 37917550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear β-catenin/c-Myc axis in OSCC.
    Wang LH; Xu M; Fu LQ; Chen XY; Yang F
    Sci Rep; 2018 Aug; 8(1):12776. PubMed ID: 30143678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway.
    Lu W; Lin C; Roberts MJ; Waud WR; Piazza GA; Li Y
    PLoS One; 2011; 6(12):e29290. PubMed ID: 22195040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction: The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression.
    Guo Y; Zhu H; Xiao Y; Guo H; Lin M; Yuan Z; Yang X; Huang Y; Zhang Q; Bai Y
    Cell Death Dis; 2022 Apr; 13(4):366. PubMed ID: 35440080
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeting Wnt/β-catenin by anthelmintic drug niclosamide overcomes paclitaxel resistance in esophageal cancer.
    Wei W; Liu H; Yuan J; Yao Y
    Fundam Clin Pharmacol; 2021 Feb; 35(1):165-173. PubMed ID: 32579788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine.
    Jung DB; Yun M; Kim EO; Kim J; Kim B; Jung JH; Wang E; Mukhopadhyay D; Hammond E; Dredge K; Shridhar V; Kim SH
    Oncotarget; 2015 Mar; 6(7):4992-5004. PubMed ID: 25669977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DKK3 blocked translocation of β-catenin/EMT induced by hypoxia and improved gemcitabine therapeutic effect in pancreatic cancer Bxpc-3 cell.
    Guo Q; Qin W
    J Cell Mol Med; 2015 Dec; 19(12):2832-41. PubMed ID: 26395974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FAT4 overexpression promotes antitumor immunity by regulating the β-catenin/STT3/PD-L1 axis in cervical cancer.
    Wang D; Wu S; He J; Sun L; Zhu H; Zhang Y; Liu S; Duan X; Wang Y; Xu T
    J Exp Clin Cancer Res; 2023 Sep; 42(1):222. PubMed ID: 37658376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma
    Zhou J; Jin B; Jin Y; Liu Y; Pan J
    Theranostics; 2017; 7(6):1447-1462. PubMed ID: 28529629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of DK419, a potent inhibitor of Wnt/β-catenin signaling and colorectal cancer growth.
    Wang J; Mook RA; Ren XR; Zhang Q; Jing G; Lu M; Spasojevic I; Lyerly HK; Hsu D; Chen W
    Bioorg Med Chem; 2018 Nov; 26(20):5435-5442. PubMed ID: 30274939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rab11a sustains GSK3β/Wnt/β-catenin signaling to enhance cancer progression in pancreatic cancer.
    Yu L; Li X; Li H; Chen H; Liu H
    Tumour Biol; 2016 Oct; 37(10):13821-13829. PubMed ID: 27481517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of β-catenin signaling suppresses pancreatic tumor growth by disrupting nuclear β-catenin/TCF-1 complex: critical role of STAT-3.
    Pramanik KC; Fofaria NM; Gupta P; Ranjan A; Kim SH; Srivastava SK
    Oncotarget; 2015 May; 6(13):11561-74. PubMed ID: 25869100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of Wnt/β-catenin and RAS/ERK pathways provides a therapeutic strategy for gemcitabine-resistant pancreatic cancer.
    Ryu WJ; Han G; Lee SH; Choi KY
    Biochem Biophys Res Commun; 2021 Apr; 549():40-46. PubMed ID: 33662667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wogonoside Inhibits Prostate Cancer Cell Growth and Metastasis via Regulating Wnt/β-Catenin Pathway and Epithelial-Mesenchymal Transition.
    Wei C; Jing J; Zhang Y; Fang L
    Pharmacology; 2019; 104(5-6):312-319. PubMed ID: 31480051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Shikonin inhibits triple-negative breast cancer-cell metastasis by reversing the epithelial-to-mesenchymal transition via glycogen synthase kinase 3β-regulated suppression of β-catenin signaling.
    Chen Y; Chen ZY; Chen L; Zhang JY; Fu LY; Tao L; Zhang Y; Hu XX; Shen XC
    Biochem Pharmacol; 2019 Aug; 166():33-45. PubMed ID: 31071331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silencing of lemur tyrosine kinase 2 restricts the proliferation and invasion of hepatocellular carcinoma through modulation of GSK-3β/Wnt/β-catenin signaling.
    Zhao G; Song Y; Dong L; Shi H; Li H; Yang L; Wang J
    Biochem Biophys Res Commun; 2019 Oct; 517(4):722-728. PubMed ID: 31395338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-300 promotes apoptosis and inhibits proliferation, migration, invasion and epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway by targeting CUL4B in pancreatic cancer cells.
    Zhang JQ; Chen S; Gu JN; Zhu Y; Zhan Q; Cheng DF; Chen H; Deng XX; Shen BY; Peng CH
    J Cell Biochem; 2018 Jan; 119(1):1027-1040. PubMed ID: 28685847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling.
    Yin L; Gao Y; Zhang X; Wang J; Ding D; Zhang Y; Zhang J; Chen H
    Oncotarget; 2016 Jul; 7(27):42126-42138. PubMed ID: 27363012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer.
    King ML; Lindberg ME; Stodden GR; Okuda H; Ebers SD; Johnson A; Montag A; Lengyel E; MacLean Ii JA; Hayashi K
    Oncogene; 2015 Jun; 34(26):3452-62. PubMed ID: 25174399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.